Stroke Prevention Device Obtains Favorable Results
An implantable device designed to prevent strokes and serious complications from common cardiac procedures received positive results in a preclinical study on sheep that measured safety and performance.
The Aortic Embolic Protection Device (AEPD), developed by MIV Therapeutics’ SagaX subsidiary, is an instrument that is positioned in the aorta as a deflector and filter to prevent migration of embolic particles and blood clots. These objects can obstruct or block blood vessels supplying the brain, causing strokes that can result in brain damage, disability or death.
The results reinforce the device’s potential as a viable preventive tool to fight strokes in cardiac patients.
More like this
- MIV Therapeutics Sells Subsidiary for $4 Million
- Bioconvertible IVC Filters Could Eliminate Retrieval and Other Complications in Patients
- Medtronic Releases Embolic Protection Device in Europe
- SVG Embolic Device Now Cleared for Carotids
- FDA Clears Lumen Biomedical’s FiberNet Embolic Protection System for Carotid Artery Stenting